Pediatric ERCP: leaving no stone unturned

ERCP has been proven to be an invaluable modality for treating a variety of pancreaticobiliary diseases for almost half a century. Although the risk:benefit ratio favors a variety of therapies applied during ERCP, adverse events are seen, and depending upon indication can range between 1% and 8%.1Jeurnink S.M. Siersema P.D. Steyerberg E.W. et al.Predictors of complications after endoscopic retrograde cholangiopancreatography: a prognostic model...